The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma
Open accessAbstract
In most cases, sorafenib-resistant HCC cells exhibit significant mesenchymal phenotype and stemness features. In this context, tumor cells might undergo cell fate transition in response to sorafenib or other targeted drugs in the presence or absence of genetic mutations. Therefore, understanding the major characteristics of drug-resistant cells state helps to discover new treatments that overcome drug resistance. To note, little is known about the metabolic or microenvironmental aspects of the certain tumor cell states beyond the genome. This review mainly focuses on the underlying mechanisms of acquired sorafenib resistance based on CSCs and EMT models, which explain tumor heterogeneity and have been considered the major cause of secondary sorafenib resistance. In particular, it discusses how the tumor microenvironment and tumor metabolism regulate cell stemness, mesenchymal state, and sorafenib resistance through epigenetic regulations, and provides reliable targets that might have synergetic effect with sorafenib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chen, C.-L., Uthaya Kumar, D. B., Punj, V., Xu, J., Sher, L., Tahara, S. M., Hess, S., & Machida, K. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.004 · Cited by 388
Self-citationRetractedGlobal cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Self-citationSorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Metabolic regulation of gene expression by histone lactylation
Zhang, D., Tang, Z., Huang, H., Zhou, G., Cui, C., Weng, Y., Liu, W., Kim, S., Lee, S., Perez-Neut, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1678-1 · Cited by 4,371
Sun, X., Ou, Z., Chen, R., Niu, X., Chen, D., Kang, R., & Tang, D. (2016) · Hepatology · doi:10.1002/hep.28251 · Cited by 2,012 · cited 2×
“Activation of the p62/ Keap1/NRF2 pathway protected against sorafenib-induced ferroptosis by directly modulating ferrous iron (Fe) metabolism genes in HCC [64].”
BackgroundDependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Viswanathan, V. S., Ryan, M. J., Dhruv, H. D., Gill, S., Eichhoff, O. M., Seashore-Ludlow, B., Kaffenberger, S. D., Eaton, J. K., Shimada, K., Aguirre, A. J., et al. (2017) · Nature · doi:10.1038/nature23007 · Cited by 2,011
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771 · cited 2×
“Cytokines and chemokines secreted from immune cells such as TGF-b, IL-6, HGF, and COX2 might be responsible for the stroma-mediated cell state transition and sorafenib resistance, given that TGF-b/SMAD, IL-6/STAT3, HGF/MET, COX2/HIF-1a and TNFa/NF-kB pathways have been widely recognized as inducers of EMT, stemness, a…”
BackgroundIdentification of the tumour transition states occurring during EMT
Pastushenko, I., Brisebarre, A., Sifrim, A., Fioramonti, M., Revenco, T., Boumahdi, S., Van Keymeulen, A., Brown, D., Moers, V., Lemaire, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0040-3 · Cited by 1,495
Zhou, S.-L., Zhou, Z.-J., Hu, Z.-Q., Huang, X.-W., Wang, Z., Chen, E.-B., Fan, J., Cao, Y., Dai, Z., & Zhou, J. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.040 · Cited by 852
Metallothionein‐1G facilitates sorafenib resistance through inhibition of ferroptosis
Sun, X., Niu, X., Chen, R., He, W., Chen, D., Kang, R., & Tang, D. (2016) · Hepatology · doi:10.1002/hep.28574 · Cited by 703
Fiaschi, T., Marini, A., Giannoni, E., Taddei, M. L., Gandellini, P., De Donatis, A., Lanciotti, M., Serni, S., Cirri, P., & Chiarugi, P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1949 · Cited by 578
Cooke, V. G., LeBleu, V. S., Keskin, D., Khan, Z., O'Connell, J. T., Teng, Y., Duncan, M. B., Xie, L., Maeda, G., Vong, S., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.11.024 · Cited by 530
Therapy-induced tumour secretomes promote resistance and tumour progression
Obenauf, A. C., Zou, Y., Ji, A. L., Vanharanta, S., Shu, W., Shi, H., Kong, X., Bosenberg, M. C., Wiesner, T., Rosen, N., et al. (2015) · Nature · doi:10.1038/nature14336 · Cited by 494
Fan, Q.-M., Jing, Y.-Y., Yu, G.-F., Kou, X.-R., Ye, F., Gao, L., Li, R., Zhao, Q.-D., Yang, Y., Lu, Z.-H., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.05.008 · Cited by 458
Chen, Y., Ramjiawan, R. R., Reiberger, T., Ng, M. R., Hato, T., Huang, Y., Ochiai, H., Kitahara, S., Unan, E. C., Reddy, T. P., et al. (2015) · Hepatology · doi:10.1002/hep.27665 · Cited by 451
Lally, J. S. V., Ghoshal, S., DePeralta, D. K., Moaven, O., Wei, L., Masia, R., Erstad, D. J., Fujiwara, N., Leong, V., Houde, V. P., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.08.020 · Cited by 410
Zhang, W., Zhu, X.-D., Sun, H.-C., Xiong, Y.-Q., Zhuang, P.-Y., Xu, H.-X., Kong, L.-Q., Wang, L., Wu, W.-Z., & Tang, Z.-Y. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2904 · Cited by 374
Apicella, M., Giannoni, E., Fiore, S., Ferrari, K. J., Fernández-Pérez, D., Isella, C., Granchi, C., Minutolo, F., Sottile, A., Comoglio, P. M., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.08.006 · Cited by 299
Liang, Y., Zheng, T., Song, R., Wang, J., Yin, D., Wang, L., Liu, H., Tian, L., Fang, X., Meng, X., et al. (2013) · Hepatology · doi:10.1002/hep.26224 · Cited by 289
Self-citationLi, Q., Pan, X., Zhu, D., Deng, Z., Jiang, R., & Wang, X. (2019) · Hepatology · doi:10.1002/hep.30671 · Cited by 287
Zhang, J., Zhang, Q., Lou, Y., Fu, Q., Chen, Q., Wei, T., Yang, J., Tang, J., Wang, J., Chen, Y., et al. (2018) · Hepatology · doi:10.1002/hep.29681 · Cited by 286
Chen, L., Guo, P., He, Y., Chen, Z., Chen, L., Luo, Y., Qi, L., Liu, Y., Wu, Q., Cui, Y., et al. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0534-9 · Cited by 253
Transketolase counteracts oxidative stress to drive cancer development
Xu, I. M.-J., Lai, R. K.-H., Lin, S.-H., Tse, A. P.-W., Chiu, D. K.-C., Koh, H.-Y., Law, C.-T., Wong, C.-M., Cai, Z., Wong, C. C.-L., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508779113 · Cited by 251
Tian, X.-P., Wang, C.-Y., Jin, X.-H., Li, M., Wang, F.-W., Huang, W.-J., Yun, J.-P., Xu, R.-H., Cai, Q.-Q., & Xie, D. (2019) · Theranostics · doi:10.7150/thno.30958 · Cited by 246
Wei, Y., Chen, X., Liang, C., Ling, Y., Yang, X., Ye, X., Zhang, H., Yang, P., Cui, X., Ren, Y., et al. (2020) · Hepatology · doi:10.1002/hep.30795 · Cited by 244
Wu, F.-Q., Fang, T., Yu, L.-X., Lv, G.-S., Lv, H.-W., Liang, D., Li, T., Wang, C.-Z., Tan, Y.-X., Ding, J., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.04.019 · Cited by 241
Zhou, S., Yin, D., Hu, Z., Luo, C., Zhou, Z., Xin, H., Yang, X., Shi, Y., Wang, Z., Huang, X., et al. (2019) · Hepatology · doi:10.1002/hep.30630 · Cited by 226
Allen, E., Miéville, P., Warren, C. M., Saghafinia, S., Li, L., Peng, M.-W., & Hanahan, D. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.029 · Cited by 221 · cited 1×
“The co-existence of hypoxic and normoxic regions has been identified inside tumors in terms of the relative proximity to blood vessels in vivo [58].”
BackgroundCui, C.-P., Wong, C. C.-L., Kai, A. K.-L., Ho, D. W.-H., Lau, E. Y.-T., Tsui, Y.-M., Chan, L.-K., Cheung, T.-T., Chok, K. S.-H., Chan, A. C. Y., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313264 · Cited by 212
Chen, Y., Huang, Y., Reiberger, T., Duyverman, A. M., Huang, P., Samuel, R., Hiddingh, L., Roberge, S., Koppel, C., Lauwers, G. Y., et al. (2014) · Hepatology · doi:10.1002/hep.26790 · Cited by 211
Lachenmayer, A., Toffanin, S., Cabellos, L., Alsinet, C., Hoshida, Y., Villanueva, A., Minguez, B., Tsai, H.-W., Ward, S. C., Thung, S., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.01.009 · Cited by 205
Shen, Y.-C., Ou, D.-L., Hsu, C., Lin, K.-L., Chang, C.-Y., Lin, C.-Y., Liu, S.-H., & Cheng, A.-L. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.559 · Cited by 202
Chen, Y., Chen, H.-N., Wang, K., Zhang, L., Huang, Z., Liu, J., Zhang, Z., Luo, M., Lei, Y., Peng, Y., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.09.022 · Cited by 189
Won, C., Kim, B., Yi, E. H., Choi, K., Kim, E., Jeong, J., Lee, J., Jang, J., Yoon, J., Jeong, W., et al. (2015) · Hepatology · doi:10.1002/hep.27968 · Cited by 187
van Malenstein, H., Dekervel, J., Verslype, C., Van Cutsem, E., Windmolders, P., Nevens, F., & van Pelt, J. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.10.021 · Cited by 185
Zhang, P., Wang, F., Wu, J., Wu, Y., Huang, W., Liu, D., Huang, X., Zhang, X., & Ke, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27095 · Cited by 181
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
Gao, L., Wang, X., Tang, Y., Huang, S., Hu, C.-A. A., & Teng, Y. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0478-9 · Cited by 179
Ma, M. K. F., Lau, E. Y. T., Leung, D. H. W., Lo, J., Ho, N. P. Y., Cheng, L. K. W., Ma, S., Lin, C. H., Copland, J. A., Ding, J., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.06.015 · Cited by 177
Lee, D., Xu, I. M., Chiu, D. K., Leibold, J., Tse, A. P., Bao, M. H., Yuen, V. W., Chan, C. Y., Lai, R. K., Chin, D. W., et al. (2019) · Hepatology · doi:10.1002/hep.30467 · Cited by 176
Kuczynski, E. A., Yin, M., Bar-Zion, A., Lee, C. R., Butz, H., Man, S., Daley, F., Vermeulen, P. B., Yousef, G. M., Foster, F. S., et al. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw030 · Cited by 174
Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma
Lee, D., Xu, M., Chiu, D. K., Lai, R. K., Tse, A. P., Li, L. L., Law, C., Tsang, F. H., Wei, L. L., Chan, C. Y., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90253 · Cited by 173
β-catenin-activated hepatocellular carcinomas are addicted to fatty acids
Senni, N., Savall, M., Granados, D. C., Alves‐Guerra, M., Sartor, C., Lagoutte, I., Gougèlet, A., Terris, B., Gilgenkrantz, H., Perret, C., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315448 · Cited by 171
Sounni, N. E., Cimino, J., Blacher, S., Primac, I., Truong, A., Mazzucchelli, G., Paye, A., Calligaris, D., Debois, D., De Tullio, P., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.05.022 · Cited by 169
Qu, Z., Wu, J., Wu, J., Luo, D., Jiang, C., & Ding, Y. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0430-z · Cited by 164
Huang, Q., Li, J., Xing, J., Li, W., Li, H., Ke, X., Zhang, J., Ren, T., Shang, Y., Yang, H., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.04.035 · Cited by 158
Tang, L., Zeng, J., Geng, P., Fang, C., Wang, Y., Sun, M., Wang, C., Wang, J., Yin, P., Hu, C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1707 · Cited by 157
Lü, M., Zhu, W., Wang, X., Tang, J.-J., Zhang, K., Yu, G., Shao, W., Lin, Z., Wang, S.-H., Lu, L., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.12.019 · Cited by 156
Guo, W., Sun, Y., Shen, M., Ma, X.-L., Wu, J., Zhang, C.-Y., Zhou, Y., Xu, Y., Hu, B., Zhang, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1753 · Cited by 153
LncRNA HAND2‐AS1 promotes liver cancer stem cell self‐renewal via BMP signaling
Wang, Y., Zhu, P., Luo, J., Wang, J., Liu, Z., Wu, W., Du, Y., Ye, B., Wang, D., He, L., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2018101110 · Cited by 147
Peng, L., Jiang, B., Yuan, X., Qiu, Y., Peng, J., Huang, Y., Zhang, C., Zhang, Y., Lin, Z., Li, J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0367 · Cited by 144
Martinez-Quetglas, I., Pinyol, R., Dauch, D., Torrecilla, S., Tovar, V., Moeini, A., Alsinet, C., Portela, A., Rodríguez‐Carunchio, L., Solé, M., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.09.001 · Cited by 143
Xiang, D., Sun, W. C., Zhou, T., Zhang, C., Cheng, Z., Li, S., Jiang, W., Wang, R., Fu, G., Cui, X., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-317440 · Cited by 140
Liu, R., Li, Y., Tian, L., Shi, H., Wang, J., Liang, Y., Sun, B., Wang, S., Zhou, M., Wu, L., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.11.030 · Cited by 133
Self-citationOkabayashi (1992) · International Journal of Oncology · doi:10.3892/ijo_00000058 · Cited by 132
Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma
Xu, L. X., He, M., Dai, Z., Yu, J. Q., Wang, J., Li, X. C., Jiang, B., Ke, Z., Su, T., Peng, Z., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz103 · Cited by 132
Wong, T. L., Ng, K. Y., Tan, K. V., Chan, L.-H., Zhou, L., Che, N., Hoo, R. L. C., Lee, T. K., Richard, S., Lo, C. M., et al. (2019) · Hepatology · doi:10.1002/hep.30923 · Cited by 130
Liao, J., Liu, P., Hou, G., Shao, J., Yang, J., Liu, K., Lu, W., Wen, S., Hu, Y., & Huang, P. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0623-x · Cited by 125
Hong, X.-H., Song, R.-P., Song, H.-W., Zheng, T., Wang, J.-B., Liang, Y.-J., Qi, S., Lu, Z., Song, X., Jiang, H.-C., et al. (2013) · Gut · doi:10.1136/gutjnl-2013-305302 · Cited by 123
Self-citationBy inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma
Li, S., Dai, W., Mo, W., Li, J., Feng, J., Wu, L., Liu, T., Yu, Q., Xu, S., Wang, W., et al. (2017) · International Journal of Cancer · doi:10.1002/ijc.31022 · Cited by 118
Dietrich, P., Koch, A., FRITZ, V. K., Hartmann, A., Bosserhoff, A., & Hellerbrand, C. (2017) · Gut · doi:10.1136/gutjnl-2017-315402 · Cited by 115
PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma
Feng, J., Wu, L., Ji, J., Chen, K., Yu, Q., Zhang, J., Chen, J., Mao, Y., Wang, F., Dai, W., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1194-z · Cited by 112
Azzariti, A., Mancarella, S., Porcelli, L., Quatrale, A. E., Caligiuri, A., Lupo, L., Dituri, F., & Giannelli, G. (2016) · Hepatology · doi:10.1002/hep.28835 · Cited by 106
Zhang, C., Liu, Z., Bunker, E. N., Ramirez, A., Lee, S., Peng, Y., Tan, A. C., Eckhardt, S. G., Chapnick, D. A., & Liu, X. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.783175 · Cited by 104
Chen, Y.-L., Lv, J., Ye, X., Sun, M., Xu, Q., Liu, C., Min, L., Li, H., Liu, P., & Ding, X. (2011) · Hepatology · doi:10.1002/hep.24254 · Cited by 101
Xu, J., Lin, H. M., Li, G., Sun, Y., Chen, J., Shi, L., Cai, X., & Chang, C. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.07.013 · Cited by 95
Self-citationDong, X., Liu, T., Zhi, X., Zou, J., Zhong, J., Li, T., Mo, X.-L., Zhou, W., Guo, W., Liu, X., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2725 · Cited by 95
Ma, M., Xu, H., Liu, G., Wu, J., Li, C., Wang, X., Zhang, S., Xu, H., Ju, S., Wei, C., et al. (2019) · Hepatology · doi:10.1002/hep.30602 · Cited by 93
Teng, Y., Zhao, H., Gao, L., Zhang, W., Shull, A. Y., & Shay, C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2039 · Cited by 92
Ma, L., Li, G., Zhu, H., Dong, X., Zhao, D., Jiang, X. L., Li, J., Qiao, H., Ni, S., & Sun, X. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.011 · Cited by 90
Wei, Z., Jia, J., Heng, G., Xu, H., Shan, J., Wang, G., Liu, C., Xia, J., Zhou, H., Wu, M. C., et al. (2019) · Hepatology · doi:10.1002/hep.30622 · Cited by 86
Prieto‐Domínguez, N., Méndez‐Blanco, C., Carbajo‐Pescador, S., Fondevila, F., Palomo, A. G., González‐Gallego, J., & Mauriz, J. L. (2017) · Oncotarget · doi:10.18632/oncotarget.20592 · Cited by 83
Differentiation Therapy by Epigenetic Reconditioning Exerts Antitumor Effects on Liver Cancer Cells
Gailhouste, L., Liew, L. C., Yasukawa, K., Hatada, I., Tanaka, Y., Nakagama, H., & Ochiya, T. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.018 · Cited by 81
Reyes, R., Wani, N. A., Ghoshal, K., Jacob, S. T., & Motiwala, T. (2016) · Gene Expression · doi:10.3727/105221616x693855 · Cited by 78
Song, Z., Liu, T., Chen, J., Ge, C., Zhao, F., Zhu, M., Chen, T., Cui, Y., Tian, H., Yao, M., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.06.016 · Cited by 71
Xu, J., Zheng, L., Jiang, C., Sun, Y., Lin, H. M., Jin, R., Tang, M., Liang, X., & Cai, X. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.411 · Cited by 70
Self-citationPositive feedback loop between cancer stem cells and angiogenesis in hepatocellular carcinoma
Yao, H., Liu, N., Lin, M. C.-M., & Zheng, J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.03.014 · Cited by 69
Guan, D., Shi, J., Zhang, Y., Zhao, J., Long, L., Chen, T., Zhang, E., Feng, Y., Bao, W., Deng, Y., et al. (2015) · Hepatology · doi:10.1002/hep.28117 · Cited by 67
Xiao, Y., Sun, Y., Liu, G., Zhao, J., Gao, Y., Yeh, S., Gong, L., & Chang, C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.11.004 · Cited by 65
Masuda, M., Chen, W., Miyanaga, A., Nakamura, Y., Kawasaki, K., Sakuma, T., Ono, M., Chen, C., Honda, K., & Yamada, T. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.033845 · Cited by 60
Zhang, H., Wang, M.-D., Zhou, X., Qin, C., Fu, G., Tang, L., Wu, H., Huang, S., Zhao, L., Zeng, M., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.11.023 · Cited by 60
Chen, Y., Hao, X., Sun, R., Wei, H., & Tian, Z. (2018) · Hepatology · doi:10.1002/hep.30317 · Cited by 55
Yoo, J., Yu, S. J., Na, J., Kim, K., Cho, Y. Y., Lee, Y. B., Cho, E. J., Lee, J., Kim, Y. J., Youn, H., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061292 · Cited by 42
PFKFB3/HIF-1α feedback loop modulates sorafenib resistance in hepatocellular carcinoma cells
Qian, L., Zou, X., Song, Y., Duan, Z., & Liu, L. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.03.109 · Cited by 41
Bort, A., Sánchez, B. G., Mateos‐Gómez, P. A., Vara‐Ciruelos, D., Rodríguez‐Henche, N., & Díaz‐Laviada, I. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12488 · Cited by 40
Liang, Y., Chen, J., Yu, Q., Ji, T., Zhang, B., Xu, J., Dai, Y., Xie, Y., Lin, H. M., Liang, X., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1228 · Cited by 34
Self-citationXu, J., Lin, H. M., Li, G., Sun, Y., Shi, L., Ma, W., Chen, J., Cai, X., & Chang, C. (2016) · International Journal of Cancer · doi:10.1002/ijc.30446 · Cited by 33
Self-citationSohn, B. H., Park, I. Y., Shin, J., Yim, S. Y., & Lee, J. (2018) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.174 · Cited by 32
Ježek, J., Plecitá‐Hlavatá, L., & Ježek, P. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00637 · Cited by 20
Cited by
The immunological and metabolic landscape in primary and metastatic liver cancer
Li, X., Ramadori, P., Pfister, D., Seehawer, M., Zender, L., & Heikenwalder, M. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00383-9 · Cited by 616
Yao, L., Zhao, M.-M., Luo, Q.-W., Zhang, Y.-C., Liu, T.-T., Yang, Z., Liao, M., Tu, P., & Zeng, K.-W. (2022) · ACS Nano · doi:10.1021/acsnano.2c01619 · Cited by 289
Xu, J., Wan, Z., Tang, M., Lin, Z., Jiang, S., Ji, L., Gorshkov, K., Mao, Q., Xia, S., Cen, D., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01281-8 · Cited by 287
Self-citation
Metadata
- Authors
- Xia, S., Pan, Y., Liang, Y., Xu, J., & Cai, X.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 51
- Pages
- 102610
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2999483628
- Cited by
- 297
- References
- 90
- FWCI
- 18.09
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.